2018
DOI: 10.1017/9781108399852
|View full text |Cite
|
Sign up to set email alerts
|

Samuel Beckett and the Visual

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
3
1
1

Relationship

0
5

Authors

Journals

citations
Cited by 8 publications
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…19 In Victoria, one third of people diagnosed with hepatocellular carcinoma (HCC) die within a month, and median survival time is less than one year. 20 On March 1 2016, several direct-acting antiviral (DAA) agents for hepatitis C were listed on the Pharmaceutical Benefits Scheme (PBS), meaning that shorter, more effective, and better-tolerated interferon-free treatment regimens are now available to Australians living with hepatitis C. 21 However, unless substantially increased numbers of people access treatment, the full public health benefit of these new therapies will not be realised. 9 In 2010, it was estimated that increasing the uptake of interferon-based therapy to 12,000 people per year from 2014 -only 5% of all those living with chronic hepatitis C -would result in cost savings of $9 million per year over three decades.…”
Section: Limited Provision Of Diagnostic Services To Victorians Livinmentioning
confidence: 99%
“…19 In Victoria, one third of people diagnosed with hepatocellular carcinoma (HCC) die within a month, and median survival time is less than one year. 20 On March 1 2016, several direct-acting antiviral (DAA) agents for hepatitis C were listed on the Pharmaceutical Benefits Scheme (PBS), meaning that shorter, more effective, and better-tolerated interferon-free treatment regimens are now available to Australians living with hepatitis C. 21 However, unless substantially increased numbers of people access treatment, the full public health benefit of these new therapies will not be realised. 9 In 2010, it was estimated that increasing the uptake of interferon-based therapy to 12,000 people per year from 2014 -only 5% of all those living with chronic hepatitis C -would result in cost savings of $9 million per year over three decades.…”
Section: Limited Provision Of Diagnostic Services To Victorians Livinmentioning
confidence: 99%